Acurx Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ACXP Nasdaq 2836 www.acurxpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acurx Pharmaceuticals, Inc.

New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global - Sep 19th, 2026 9:45 am
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures - Sep 14th, 2026 6:01 am
Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ... - Aug 20th, 2026 7:02 pm
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat - Aug 17th, 2026 6:01 am
Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Aug 14th, 2026 10:56 am
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update - Aug 14th, 2026 5:01 am
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics - Aug 12th, 2026 6:01 am
Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics - Aug 10th, 2026 6:01 am
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection - Aug 3rd, 2026 6:00 am
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection - Jul 14th, 2026 6:00 am
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update - Jul 8th, 2026 6:00 am
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference - Jun 16th, 2026 6:00 am
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why - Jun 8th, 2026 10:00 am
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat - May 19th, 2026 10:25 am
Acurx Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - May 12th, 2026 11:05 am
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update - May 12th, 2026 5:01 am
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026 - May 4th, 2026 6:00 am
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase - Apr 29th, 2026 6:00 am
Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit - Apr 27th, 2026 6:00 am